
ASTH Stock Forecast & Price Target
ASTH Analyst Ratings
Bulls say
Astrana Health is a strong performer in the health care industry, as shown by its projected MA rate increase and partnerships with major payers resulting in revenue growth. Its utilization of technology and data analytics to provide value-based care and recent acquisition of Prospect Medical indicate potential for further growth. Comparison to a similar company, EVH, suggests ASTH may also have good cost control measures.
Bears say
Astrana Health is facing several challenges that could negatively impact its performance and stock price. These include declining enrollment in both Medicaid and Exchange segments, tighter eligibility regulations, and margin pressure. The company has also faced volatility in its segment reporting and reserves. While Astrana Health has a healthy cash flow, a strong balance sheet, and potential synergies with its recent acquisition, there is uncertainty around its claims visibility and reserve adequacy. Additionally, the company operates in a highly regulated industry with potential reimbursement and regulatory pressures. These risks, combined with the company's high valuation, make it a risky investment option.
This aggregate rating is based on analysts' research of Astrana Health Inc and is not a guaranteed prediction by Public.com or investment advice.
ASTH Analyst Forecast & Price Prediction
Start investing in ASTH
Order type
Buy in
Order amount
Est. shares
0 shares